{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:45Z","timestamp":1792404045206,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.diagmicrobio.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T11:51:06Z","timestamp":1523706666000},"page":"78-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC\/PDA: role of azole metabolic rate"],"prefix":"10.1016","volume":"92","author":[{"given":"Alicia","family":"Gomez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alcazar-Fuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Bernal-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jchromb.2016.10.035","article-title":"Development and validation of LC-MS\/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism","volume":"1038","author":"Al-Ghobashy","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0010","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/AAC.00046-13","article-title":"Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation","volume":"57","author":"Amsden","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0025","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1469-0691.2011.03732.x","article-title":"HPLC\/UV or bioassay: two valid methods for posaconazole quantification in human serum samples","volume":"18","author":"Cendejas-Bueno","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2013.03.012","article-title":"A simple, sensitive HPLC-PDA method for the quantification of itraconazole and hydroxy itraconazole in human serum: a reference laboratory experience","volume":"76","author":"Cendejas-Bueno","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eimc.2012.03.003","article-title":"Development and validation of a fast HPLC\/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experience","volume":"31","author":"Cendejas-Bueno","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic Drug Monitoring of Posaconazole: an Update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/00498254.2010.503814","article-title":"Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring","volume":"40","author":"Eiden","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0055","series-title":"Guideline Bioanalytical method validation","author":"EMEA","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0060","series-title":"Guidance for Industry, Bioanalytical Method Validation","author":"FDA","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0020","series-title":"Drug Interaction Studies. Guidance for Industry, draft guidance","author":"FDA","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0065","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","article-title":"Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring","volume":"33","author":"Hassan","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0080","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9673(01)94634-5","article-title":"Sensitive method for the measurement of amiodarone and desethylamiodarone in serum and tissue and its application to disposition studies","volume":"385","author":"Kannan","year":"1987","journal-title":"J Chromatogr"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","article-title":"Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies","volume":"95","author":"Ke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.1995.450","article-title":"Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?","volume":"72","author":"Lennard","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0110","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13318-017-0417-y","article-title":"The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes","volume":"42","author":"Mikov","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2012.10.028","article-title":"Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole","volume":"415","author":"Mino","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0130","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2010.119","article-title":"Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data","volume":"88","author":"Templeton","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2015.11.011","article-title":"Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation","volume":"22","author":"Teusink","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0150","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000235","article-title":"Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease","volume":"37","author":"van der Elst","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0155","series-title":"United Kingdom National External Quality Assessment Schemes","author":"www.ukneqas.org.uk","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinbiochem.2011.11.004","article-title":"Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application","volume":"45","author":"Yamada","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.diagmicrobio.2018.04.003_bb0165","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/dmd.114.059345","article-title":"Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group","volume":"43","author":"Yu","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T16:50:50Z","timestamp":1571158250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0732889318301160"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.04.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC\/PDA: role of azole metabolic rate","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}